News about Global Pharma

Fortress Biotech Unit Cyprium to Sell Rare Pediatric PRV for USD 205 Million

Fortress Biotech Inc and its majority-owned subsidiary Cyprium Therapeutics Inc announced that Cyprium has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 205 million, subject to closing.

Global Pharma | 25/02/2026 | By Darshana |  153

Worldwide Clinical Trials Completes Acquisition of Oncology-Focused CRO Catalyst Clinical Research

Worldwide Clinical Trials strengthens its oncology and early-phase research capabilities following the completion of its acquisition of Catalyst Clinical Research.

Global Pharma | 17/02/2026 | By News Bureau |  182

Sanofi Completes Acquisition of Dynavax, Expands Adult Vaccine Portfolio with HEPLISAV-B

Sanofi has finalised its acquisition of Dynavax, adding hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate to strengthen its global adult immunisation business.

Global Pharma | 12/02/2026 | By News Bureau |  202

Pfizer Joins BaseLaunch Biotech Incubator

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures.

Global Pharma | 12/02/2026 | By News Bureau |  259

FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy

Affinia Therapeutics receives FDA clearance to begin clinical testing of AFTX-201, a next-generation AAV gene therapy for BAG3-associated dilated cardiomyopathy, with Phase 1/2 UPBEAT trial set to begin in 2026.

Global Pharma | 09/02/2026 | By News Bureau |  186

Health Canada Authorises Livmarli Tablet for Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals receives Health Canada approval for Livmarli tablet formulation, expanding dosing options for eligible Alagille syndrome patients with cholestatic pruritus.

Global Pharma | 07/02/2026 | By News Bureau |  140

Pfizer Launches Cost Savings Programme on TrumpRx

Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.

Global Pharma | 07/02/2026 | By News Bureau |  169

Lupin Launches Topiramate Extended-Release Capsules in US Following FDA Approval

Lupin rolls out FDA-approved generic topiramate extended-release capsules in the US for epilepsy and migraine treatment.

Global Pharma | 05/02/2026 | By News Bureau |  169

Slingshot Biosciences to Expand into UK and EU Markets

Slingshot Biosciences is expanding its operations into the United Kingdom and European Union to scale deployment of its precision-engineered synthetic cell mimic technology and accelerate cell and gene therapy as well as broader pharmaceutical development.

Global Pharma | 05/02/2026 | By News Bureau |  115

Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026

Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.

Global Pharma | 05/02/2026 | By Darshana |  576